Anja Seckinger

7PUBLICATIONS
49CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyMedical mycologyProteins and peptidesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.

Qian Shi, Bruno Paiva, Levi D Pederson

|Jun 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries.

Anja Seckinger, Hans Salwender, Hans Martin

|Apr 10, 2024
Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics.

Martin Kuric, Susanne Beck, Doris Schneider

|Apr 12, 2022
Resemblance-Ranking Peptide Library to Screen for Binders to Antibodies on a Peptidomic Scale.

Felix Jenne, Sergey Biniaminov, Nathalie Biniaminov

|Nov 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.

Jacob Stroh, Anja Seckinger, Michael Heider

|Oct 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.

Eva-Maria Klein, Diana Tichy, Hans J Salwender

Pageof 2

Frequent Collaborators

4 joint publications

Hartmut Goldschmidt

2 joint publications

Dirk Hose

1 joint publications

Guy Ledergor

1 joint publications

Rachael L Terry